PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary ...

Immunology biotech Agomab Therapeutics is seeking to raise up to $212.5 million in its Nasdaq debut, joining a series of biotechs chipping away at 2025’s iced-over IPO market. The Belgium-based ...

Welcome to Fierce Biotech's fifth annual layoff tracker, a resource designed to keep pace with the sector's steady stream of workforce reductions. In 2025, industry layoffs continued to rise year over ...

To share your story, or find out how to get involved with CNBC Cures, email CNBC.cures@cnbc.com China is pumping money into its biotech industry, helping launch a new wave of labs and incubators in ...

Plus: read our predictions for the five hottest AI trends to watch This is today's edition of The Download, our weekday newsletter that provides a daily dose of what's going on in the world of ...

A run of pharmaceutical mergers and acquisitions is fueling optimism that biotechnology venture capital is poised to rebound from its postpandemic slump. With $223 billion in biotech M&A deals ...

Why personalized gene editing, genetic resurrections and embryo scoring made our list. Earlier this week, MIT Technology Review published its annual list of Ten Breakthrough Technologies. As always, ...

Arthur Herman’s op-ed, “America Is the Sole Superpower Again,” (Jan. 15) asserts that China is “sliding into a distant second place” in the battle for economic, military and technological supremacy.

Krystal Biotech is upgraded to Strong Buy, driven by Vyjuvek's commercial success and a robust catalyst-rich pipeline. KRYS boasts 96% gross margins, nearly $1B in cash, and a platform poised to ...